Most mitotically competent mammalian cell types can react to stress by undergoing a phenotypically distinctive and permanent form of growth arrest called "cellular senescence". This response has been extensively characterised in cell culture and more recently it has been found to occur also in vivo in a number of tissues. In this review I will present the case for the occurrence of senescence in the vascular endothelium. I will also discuss the mechanisms and factors that modulate endothelial cell replicative capacity and the onset of senescence. Finally, I will examine the senescent phenotype and its possible consequences for the development and progression of vascular diseases.
EVIDENCE THAT ENDOTHELIAL CELL SENESCENCE OCCURS IN VIVO
While the occurrence of senescence in cell culture has been extensively documented, it is only recently that the importance of this phenomenon in vivo has begun to be appreciated. Senescent cells have been found in a number of mammalian tissues in association with ageing, age-related pathologies, hyperplastic lesions and cellular stress (reviewed in 8; 19). In the case of the endothelium, firm evidence of its occurrence was obtained by several laboratories using senescence-associated β galactosidase (SA-β-gal) as a histochemical marker. Using this method senescent endothelial cells were found to accumulate after repeated balloon endothelial denudation of the rabbit carotid artery, an injury model that provokes endothelial and smooth muscle cell proliferation (24) . Similarly, other laboratories demonstrated the presence of senescent endothelial cells overlying atherosclerotic plaques of human aorta and coronary arteries (57; 90) and in the aortae of diabetic rats (12). In addition, the occurrence of stress-induced endothelial cell senescence has recently been demonstrated in a murine model of oxidative stress (70) .
The occurrence of endothelial cell senescence in vivo has also been inferred from examination of telomere length in the vasculature. A number of independent studies have shown that telomeres in the endothelium shorten with age and that this erosion is more pronounced in atherosclerosis-prone areas (2; 10; 67). Furthermore, a study examining the relationship between telomere length and coronary artery disease found that telomeres in endothelial cells derived from diseased portions of arteries were shorter than those from non-diseased regions (66).
FACTORS AFFECTING ENDOTHELIAL CELL SENESCENCE
Studies on cultured endothelial cells have shown that the onset of senescence can be modulated by a plethora of factors affecting vascular function. These include mitogens (48), inflammatory molecules (5), angiotensin II (40), oxidants and antioxidants (26; 47), nitric oxide (89) , high glucose (96) , advanced glycation endproducts (AGEs) (12) and mitochondria (74) . Most of these factors influence senescence via two main processes: by altering the intracellular levels of cellular oxidative stress and/or by modulating telomerase activity ( Figure 1 ).
Oxidative stress
Oxidative stress is a major stimulus for the induction of senescence (62) . A substantial body of evidence indicates that in endothelial cells reactive oxygen species (ROS) generated from either intracellular or extracellular sources, can induce or accelerate the development of senescence by acting at multiple sub-cellular levels (20). As indicated above, telomeres are particularly susceptible to oxidative damage. In addition, besides affecting telomeres directly, or indirectly via inhibition of telomerase (see below), ROS can induce senescence by telomere-independent mechanisms. The latter include direct damage to genomic DNA, mitochondrial damage and activation of cytosolic stress response kinases or other redox-sensitive signaling proteins which have been implicated in senescence responses (Figure 1 ).
Oxidative stress and telomere damage. In endothelial cells, an association between oxidative stress, accelerated telomere shortening and senescence has been suggested by studies in which the intracellular redox environment was manipulated by incubation with a vitamin C analogue (26), by exposure to homocysteine (95) or by interference with the glutathione (GSH) redox-cycle (47). In contrast, telomere dysfunction was not apparent when oxidative stress-induced senescence was caused by exposure to an AGE (12).
ROS as mediators of sustained mitogenic stimulation. Excessive mitogenic stimulation caused by forced expression of activated oncogenes is known to induce senescence (76) . In endothelial cells this phenomenon has been observed when active forms of Akt (58), Ras (80) or Rac1 (16) were over-expressed. Promotion of senescence under these conditions is thought to result from a dysregulation of the cellular redox-balance leading to an increase in ROS production which in turn may stimulate p53 activity (reviewed in 20). The pathophysiological significance of these findings may lie in the fact that pro-atherogenic conditions, such as hyperinsulinaemia, chronic inflammation and hypercholesterolaemia, are known to activate Akt-and Ras-mediated signalling in endothelial cells.
The role of mitochondria. ROS can damage mitochondrial DNA and other redoxsensitive components of this organelle, thus impairing mitochondrial function.
Mitochondria by themselves generate ROS during normal respiration and some studies suggest that when the normal function of the electron transport chain is affected ROS output may be augmented, thus increasing the oxidative burden of the cell (reviewed in 3; 52). Recently, the importance of mitochondria-derived ROS in the induction of endothelial cell senescence has been highlighted by a study examining the role of prohibitin-1 (PHB1) in this process (74) . PHB1 is a constituent of the inner mitochondrial membrane thought to be important for the maintenance of mitochondrial functional integrity (65). It has now been demonstrated that knockdown of PHB1 in endothelial cells increases mitochondrial ROS generation which causes cellular senescence (74) . In this study the induction of senescence was considered to be the consequence of a sustained ROS-dependent Akt activation. However, other ROS-induced signaling mechanisms or direct oxidative damage cannot be discounted at this stage. Aside from the precise identity of the down-stream effectors of mitochondrial ROS, the significance of this finding may have implications beyond understanding the function of PHB1 in senescence. In this regard, the complex interplay between levels of NO, oxygen availability and the redox environment may have an important role (21).
Modulation of telomerase activity
In endothelial cells levels of telomerase activity are substantially lower than those found in a typical cancer cell line or in cells from other renewable tissues (48).
Nevertheless, expression in these cells could be physiologically relevant since its overall activity is growth regulated (39; 48) and inhibition by genetic means is associated with a reduction in the replicative capacity of the cells (22) . The role of endothelial cell mitogens. A number of growth factors known to be important for endothelial homeostasis and angiogenesis have been investigated for their effects on telomerase activity and senescence (41; 48). Among these, FGF-2 was shown to enhance telomerase activity and to maintain cellular replicative life-span, in association with an increase in TERT transcripts. In contrast, VEGF-A, at concentrations that had the same mitogenic effect as FGF-2 did, had no effect on TERT levels or activity and was not able to support long term endothelial cell replication (48; 83). Another study, however, investigating the role of telomerase in angiogenesis, concluded that VEGF-A can activate telomerase via NO signaling (97) .
Other studies have shown that estrogens also increase telomerase activity in endothelial cells via transcriptional and post-translational mechanisms, the latter involving engagement of the PI3K-AKT pathway and subsequent phosphorylation of TERT (17; 41). Also in these cases the effects were accompanied by retardation of the onset of senescence.
The role of nitric oxide. It is generally assumed that nitric oxide (NO) counteracts endothelial cell senescence by stimulating telomerase activity and reducing telomere erosion (34; 89). However, experiments using a combination of pharmacological tools and silencing RNA technology suggest that this might not be the case (38). Indeed, While the above study also showed an increase in telomerase activity upon inhibition of senescence, this effect may be attributed to the maintenance of the cells in a proliferative state (48) rather than to a direct effect of SIRT-1 or NO on telomerase.
Taken together these findings suggest that NO may counteract senescence in the 
Changes affecting endothelium-dependent vasodilatation
Nitric oxide bioavailability is critical to normal endothelial function (60) . Advanced age leads to impairment of endothelial NO production (84) and to increased inactivation of NO by superoxide (87) , which contribute to age-related endothelial dysfunction (9; 98). A number of studies have investigated whether endothelial senescence may be involved in these phenomena. These studies have established that senescent endothelial cells have lower levels of eNOS activity and produce decreased levels of NO (37; 55; 73). This phenotypic change was also brought about after senescence was induced in aortic endothelial cells by introducing the dominant negative form of the telomere-binding protein TRF-2 (57). In contrast, endothelial cells bypassing senescence by ectopically expressing TERT displayed no decline in eNOS expression or NO production (55; 57). One of the most potent inducers of eNOS expression in endothelial cells is laminar shear stress. The effect of shear stress on eNOS expression was also markedly blunted in senescent endothelial cells, but again could be rescued by TERT over-expression. The same was true of the NOmediated inhibition of monocyte adhesion to the endothelial monolayer (55). Levels of another important vasodilator, prostacyclin, were also found to be reduced in endothelial cultures undergoing senescence in vitro (63) .
In contrast to endothelial cells that became senescent after successive rounds of replication, endothelial cells undergoing premature senescence due to AGE-induced oxidative stress actually increased eNOS expression, despite the fact that their ability to produce NO was reduced (12). Similarly, in the aortic wall of ageing rats in vivo, while NO production was impaired, eNOS was upregulated about sevenfold (87) . This reduction in NO bioavailability was attributed to an increase in mitochondrial-derived ROS and concomitant production of peroxynitrite (87) . Evidence of peroxynitrite formation and nitrosative stress, which could be prevented by anti-oxidant treatment, was also observed in association with senescence induced by AGEs in vitro (12) and by diabetes in vivo (6). Whilst on the one hand these findings would be consistent with the occurrence of oxidative stress-induced senescence in the vasculature, it is important to point out that senescent endothelial cells produce higher levels of ROS than their younger counterparts (85) . Hence, oxidative stress is not only a stimulus for senescence but also an outcome of this process which can also impinge on NO bioavailability.
Senescence and apoptosis
The final fate of senescent cells may also have pathophysiological consequences because, given their altered phenotype, effective removal could be more beneficial for the maintenance of endothelial homeostasis. At present it is not clear whether in vivo senescent endothelial cells are removed by an active physiological mechanism, whether they accumulate indefinitely or simply succumb to the forces of flow, eventually shedding from the endothelial surface.
Studies examining the relationship between senescence and apoptosis in endothelial cells have yielded conflicting results. One study indicated that, unlike fibroblasts, the final fate of senescent endothelial cells is to undergo apoptosis (92) . Other studies suggest that endothelial cell senescence by itself does not result in apoptosis, but rather it increases the sensitivity of these cells to apoptotic stimuli such as TNF-α and oxidised LDL (37; 80). In one case this effect has been attributed to the reduced levels of NO present in senescent cells (37) and this is consistent with the notion that physiological concentrations of NO promote cell survival (59) .
Studies in HUVEC examining the effects of p53, p21 and p16 expression on the induction of apoptosis or senescence indicate that the p53/p21 pathway is involved in the induction of both phenomena, whereas the p16 pathway is only involved in the induction of senescence (13). In addition, these studies showed that the primary role of the p53/p21 pathway is in the control of apoptosis. Thus, these findings suggest that in endothelial cells whether apoptosis occurs in association with senescence may also depend in part on the tendency of different types of stresses to engage one or both intracellular effector pathways.
SUMMARY AND FUTURE DIRECTIONS
The occurrence of endothelial cell senescence in the vasculature is gaining increasing recognition. Cell culture studies indicate that both cell turnover and oxidative stress may contribute to this phenomenon by inducing telomere shortening. Although the evidence for the occurrence of this process in the vessel wall in vivo is compelling, the existence of a causal relationship between telomere dysfunction and endothelial senescence awaits direct demonstration. In particular, while cell culture studies clearly show that endothelial cells express telomerase, that this activity is growth regulated and sensitive to the redox environment and that telomerase promotes angiogenesis in models of disease, the relevance of these laboratory findings to human adult vascular homeostasis remains to be elucidated. In addition, oxidative stress may induce senescence by telomere independent mechanisms and these may be more relevant in the context of vascular pathophysiology. Animal studies have confirmed that oxidative stress indeed induces senescence in vivo and that this may be particularly relevant in the context of type II diabetes (6). However, extending these findings to humans is currently hampered by the unavailability of non-invasive techniques to assess endothelial cell senescence in vivo. Development of new markers of endothelial cell senescence amenable to clinical investigation will help to ascertain whether pharmacological interventions, such as statins and peroxynitrite scavengers, which have demonstrable ability to reduce senescence in laboratory models of disease (6; 79), can be also effective in the human setting. 
